Enhertu cleared for NHS use via Cancer Drugs FundNICE has recommended the use of AstraZeneca and Daiichi Sankyo’s Enhertu in draft guidance, the first time the Share XEnhertu cleared for NHS use via Cancer Drugs Fundhttps://pharmaphorum.com/news/enhertu-cleared-for-nhs-use-via-cancer-drugs-fund/
Astellas, Seagen seek speedy reviews of Padcev in bladder cancerThe next milestone in Seagen and Astellas’ bid to build their antibody-drug conjugate (ADC) Padcev into a blockbuster Share XAstellas, Seagen seek speedy reviews of Padcev in bladder cancerhttps://pharmaphorum.com/news/astellas-seagen-seek-speedy-reviews-of-padcev-in-bladder-cancer/
Pyxis follows Pfizer alliance with $152m fundraising for cancer pipelineFresh from a licensing agreement with Pfizer, US startup Pyxis Oncology has raised a sizeable $152 million in Share XPyxis follows Pfizer alliance with $152m fundraising for cancer pipelinehttps://pharmaphorum.com/news/pyxis-follows-pfizer-alliance-with-152m-fundraising-for-cancer-pipeline/
Boehringer buys NBE for €1.18bn, adding cancer ADC expertiseBoehringer Ingelheim has expanded its oncology focus for the second time this week by buying Swiss biotech NBE-Therapeutics, Share XBoehringer buys NBE for €1.18bn, adding cancer ADC expertisehttps://pharmaphorum.com/news/boehringer-buys-nbe-for-e1-18bn-adding-cancer-adc-expertise/
FDA sets May date for verdict on ADC’s lymphoma drug LoncaADC Therapeutics could claim its first product approval in the US next May, after the FDA started a Share XFDA sets May date for verdict on ADC’s lymphoma drug Loncahttps://pharmaphorum.com/news/fda-sets-may-date-for-verdict-on-adcs-lymphoma-drug-lonca/
Exelixis doubles down on ADCs for cancer with NBE, Catalent dealsExelixis made its name developing small-molecule drugs for cancer, so a new pair of deals focused on antibody-drug Share XExelixis doubles down on ADCs for cancer with NBE, Catalent dealshttps://pharmaphorum.com/news/exelixis-doubles-down-on-adcs-for-cancer-with-nbe-catalent-deals/
FDA reviewer warns of eye trouble with GSK’s myeloma ADCGlaxoSmithKline heads for an FDA advisory committee meeting this week for belantamab mafodotin – its much-touted treatment for Share XFDA reviewer warns of eye trouble with GSK’s myeloma ADChttps://pharmaphorum.com/news/fda-reviewer-warns-of-eye-trouble-with-gsks-myeloma-adc/
FDA starts quick review of Astellas/Seattle Genetics’ bladder cancer drugThe FDA has started a priority review of Seattle Genetics and Astellas’ antibody-drug conjugate enfortumab vedotin in bladder Share XFDA starts quick review of Astellas/Seattle Genetics’ bladder cancer drughttps://pharmaphorum.com/news/fda-starts-quick-review-of-astellas-seattle-genetics-bladder-cancer-drug/
Denmark’s Genmab raises a bumper $500m-plus in Nasdaq IPOGenmab has shattered recent records with its Nasdaq listing, raising $506 million to help it advance multiple antibody Share XDenmark’s Genmab raises a bumper $500m-plus in Nasdaq IPOhttps://pharmaphorum.com/news/denmarks-genmab-raises-a-bumper-500m-plus-in-nasdaq-ipo/
